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ing studies that detail the area of intervention. A
reduction in ABPI should be correlated with the
images of the treated segment to determine whether a
reduction in index has been caused by problems with-
in the treated segment or by progressive disease prox-
imal or distal to the treated segment.
Recommendation 20: Reporting intermittent claudi-
cation outcomes separately from critical limb
ischaemia
Results of treatment in patients with intermittent
claudication should be analysed separately from
those of patients with critical limb ischaemia.
83.1.3
Impact of Outcomes Assessment on Management of
Intermittent Claudication
Only through an understanding of the specific and
overall effects of vascular disease on the patient can
physicians develop appropriate therapeutic plans.
Management guidelines for treatment and definitions
of success of treatment should consider all types of
outcomes. For example, a patient with mild claudica-
tion according to the walking distance categories
should be considered for treatment if his or her quali-
ty of life is severely impacted by the disease as meas-
ured by the health-related quality-of-life measures.
Conversely, a patient with severe claudication would
not require treatment if his or her quality of life is not
affected by the disease. Success of an intervention is
defined as improvement of at least one category and
should be considered for each of the outcomes meas-
ures. If more than one attribute is measured for a par-
ticular outcome measure, improvement should be
defined as an upward shift of at least one category on
at least half of the attributes, for example, at least two
attributes on the WIQ and at least four attributes on
the 5F-36/RAND-36 (see Critical Issue 5, p 565).
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B4
TREATMENT OF INTERMITTENT CLAUDICATION
B 4.1
Overall Strategy and Basic Treatment for
Intermittent Claudication
84.1.1
Overall Strategy
The overriding issue in the management of patients
presenting with IC is that they are at significant risk of
developing severe and often fatal cardiovascular com-
plications; thus, their most serious problem is not the
limitation of walking, even though that may be their
only symptom. Patients with IC are at 2 to 4 times
greater risk of dying from the complications of gener-
alised atherosclerosis than similar people without
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claudication (see A 2.5.2, Cause of Death in
Claudicants, p 517). Therefore, the first priority in
designing a treatment plan for these patients is to try
to modify the known risk factors for the progression of
atherosclerosis and development of atherothrombotic
complications. It is important to explain to the patient
the rationale for this strategy and that it is not
designed to improve the claudication distance.
Emphasis should be put on those risk factors whose
modification has been shown to be particularly effec-
tive in decreasing morbidity and mortality, for
instance, cigarette smoking. Advice regarding this, as
well as some other risks such as obesity, has to be reg-
ularly reinforced. Modification of risk factors should
be accompanied by the long-term prescription of
antiplatelet pharmacotherapy, usually low-dose
aspirin.
The second step in the basic management in the
newly diagnosed claudicant is the reassurance of the
patient that walking into his or her claudication pain
not only does no harm, but is in fact likely to gradual-
ly increase his or her pain-free walking distance.
Regular walking exercise is likely to be beneficial both
for the leg and for the underlying general disease,
through a number of mechanisms. Risk factor modifi-
cation, antiplatelet therapy, and regular exercise train-
ing are all the treatment that most patients with IC will
need and is all that most should be offered in the cur-
rent state of our knowledge. However, the condition
of a minority of c1audicants will deteriorate, and their
handicap will become sufficiently severe to consider
some local intervention, angioplasty or surgery, for
their PAD. On rare occasions, a patient's handicap
may be so severe at presentation that intervention may
be considered even before a full trial of basic nonin-
terventional therapy. The decision to image the precise
anatomy of the lesion depends on the decision regard-
ing whether some form of intervention would be rec-
ommended if the morphology of the atherosclerotic
lesion showed it suitable for intervention.
The decision to consider a patient for interventional
therapy is arrived at by the patient balancing existing
disability against the procedural risk and likelihood of
long-term success of an intervention. The patient's
disability should be assessed in terms of not only clau-
dication distance but also the patient's job and pre-
ferred everyday activities. Thus, for instance, inter-
vention may be contemplated even in a long-distance
claudicant, say, 500 metres on the flat, if this prevents
a patient from pursuing his or her normal occupation
in the building trade. At the other extreme, a short
claudication distance might be accepted in an elderly
retired person who has no particular desire to leave
his of her home. On the other side of the equation is
the risk of imaging and then the risk of intervention.
Even if imaging is by traditional angiography, the risk
is very low. In a multicentre trial of 118,591 arterio-
graphic procedures reported by Hessel et al,' for
example, the incidences of complications with axillary,
translumbar, and femoral approaches were 3.29%,
2.89%, and 1.73% respectively; overall mortality rate
was 0.025%. (See B2.2.3, Imaging Techniques, p 561.)
The risks of the actual intervention have also been
significantly lowered by the advent of angioplasty
(PTA). Complications of PTA today are for the most
part minor and typically do not require surgical treat-
ment.s Access-related complications range from less
serious and more common (eg, groin haematoma) to
the serious but rare events (eg, retroperitoneal
haematornaj.' The incidence of complications at the
angioplasty site, 1% to 7% in most series, is similar to
that for percutaneous transluminal coronary anglo-
plasty (PTCA) and consists principally of acute occlu-
sion. Many of these can be managed with lytic or
adjunctive mechanical therapy, including stents, so
that in expert hands the need for emergency surgery
because of a jeopardised limb is rare.
The total incidence of complications countrywide is
unknown, but it is probably higher than that reported
from specialised centres. Distal embolisation has been
reported in up to 5% of cases.' Most, however, are clin-
ically silent,2 and even those that might be potentially
problematic often can be treated successfully post-
PTA by judicious use of lytic therapy. Although these
complications are relatively minor, they and the sig-
nificant recurrence rate after PTA must be kept in
mind, and there are several randomised trials, the
most recent also employing quality-of-life measures,
that show no advantage of PTA over exercise training
with extended follow-up (see B 4.5, Comparison of
Therapeutic Options, p 5100).
Both the risks and cost of percutaneous revasculari-
sation increase with the complexity and extent of
anatomic involvement. The decision to revascularise
the patient with claudication therefore must take into
account both symptoms and the results of noninvasive
testing (see B 2, Evaluation, p 548). Once having clari-
fied the anatomic basis for claudication, the recom-
mendation to advise percutaneous revascularisation is
then individualised according to the two considera-
tions just indicated. Diagnostic angiography may sug-
gest that percutaneous revascularisation has a high
likelihood of technical success in one patient, suggest-
ing that he or she may be a suitable candidate for the
procedure. In other patients, certain risks and a com-
plex of anatomic factors suggesting a low likelihood of
acute or long-term success may dictate that only sur-
gical revascularisation would constitute effective ther-
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apy. In such a case, it may be appropriate to defer the
risk of surgery until the patient is more severely dis-
abled. Imaging thus may critical1y raise or lower the
threshold for recommending that an intervention be
performed.
Should the patient treated by percutaneous revascu-
larisation return with clinical evidence of restenosis,
repeat percutaneous intervention is probably indicat-
ed for the same reasons that led to the recommenda-
tion for the original procedure. A certain proportion of
these patients-as had been clearly documented in
certain patients undergoing one or more repeat coro-
nary angioplasty proceduresw-e-will achieve a satis-
factory long-term result after the second intervention.
If the imaging indicates primary or recurrent lesions
unsuitable for safe angioplasty, the possibility of sur-
gical reconstruction has to be considered. The risks of
this are significantly greater than the risks of angie-
plasty, in terms of not only mortality but major mor-
bidity and delay in return to normal activities.
Therefore, the assessment of the patient's general con-
dition becomes more central to deciding whether sur-
gery is warranted.
Adopting this approach with maximum concern for
safety and efficacy requires coordinated input from
experts in angiology, cardiology, radiology, and vascu-
lar surgery. Guidelines for appropriateness of inter-
vention should be laid down by a team of involved
specialists, but then individual patient management
can be based on the guidelines as interpreted by one or
two members of the team. Many centres currently per-
form an angiogram and then proceed immediately
with percutaneous revascularisation if needed. Other
centres prefer to separate the diagnostic imaging from
theinterventional procedure. These decisions require
experienced judgment, and expert advice from appro-
priate specialists on specific aspects should be
obtained as needed.
Recommendation 21: Indications for invasive ther-
apy in intermittent claudication
Before offering a patient with intermittent claudi-
cation the option of any invasive therapy, endovas-
cular or surgical, the fol1owing considerations must
be taken into account:
• A predicted or observed lack of adequate
response to exercise therapy and risk factor mod-
ification
• The patient must have a severe disability, either
being unable to perform normal work or having
very serious impairment of other activities impor-
tant to the patient
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• Absence of other disease that would limit exercise
even if the claudication was improved (eg, angina
or chronic respiratory disease)
• The individual's anticipated natural history and
prognosis
• The morphology of the lesion must be such that
the appropriate intervention would have low risk
and high probability of initial and long-term suc-
cess
Critical Issue 6: Identifying patients with intermit-
tent claudication at higher risk of progression of
peripheral arterial disease
There is a need for identification of the smal1 group
of patients with intermittent claudication who,
based on severity of symptoms, ankle:brachial
pressure index, or anatomy of the arterial lesion, or
the presence of specific risk factors, are at higher
risk of progression of peripheral arterial disease.
Pharmacotherapy aimed at increasing claudication
distance and improving functional status is under
development (see B 4.2, Pharmacotherapy for
Symptoms of Intermittent Claudication, p S76). Other
therapies designed to stimulate angiogenesis, improve
skeletal muscle metabolism, and modulate platelet
and vascular endothelial function are al1under devel-
opment to treat the symptoms of claudication.
B 4.1.2
Basic Treatment
Riskfactor modification
Modifiable atherosclerotic risk factors for PAD include
smoking, diabetes mellitus, obesity, hyperlipidaemia,
hypertension, and homocysteine elevation. These will
be considered in approximate order of importance.
Cigarette smoking In smokers, the risk of developing
PAD is increased twofold to threefold, and smoking
correlates more closely with development of intermit-
tent claudication than any other cardiovascular risk
factor," Patients with PAD who continue to smoke
have a greater likelihood of vascular disease progres-
sion, MI, stroke, and death than those who stop smok-
ing.8,9 Smoking is also closely associated with the risk
of limb 10ss.1O Based on these findings, smoking cessa-
tion is a critical step in the management of IC, even
though the effect on the claudication symptoms may
not be immediately evident." In a self-selected paral-
lel group study, there was significant difference in the
change in ankle pressure and treadmill walking dis-
tance between those patients who continued to smoke
and those who stopped.P
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Recommendation 22: Smoking cessation in periph-
eral arterial disease
All patients with peripheral arterial disease should
be strongly and repeatedly advised to stop smok-
ing. Cessation rates are likely to be enhanced by a
special program.
Obesity The weight of the patient may be directly
related to claudication distance. Overweight patients
with IC therefore directly benefit from reducing
weight in terms of claudication distance. In addition,
obesity is a recognised risk factor of most fatal and
nonfatal cardiovascular events.
Diabetes mellitus Diabetes mellitus is highly associ-
ated with lower-extremity arterial disease and its pro-
gression.13,U,15,16 Although glycaernic control correlates
well with an improvement in most diabetic complica-
tions, there is conflicting evidence about a direct cor-
relation between glycaemic control and the severity or
progression of PAD.J5,17,18,19,20 The United Kingdom
Prospective Diabetes Study (UKPDS) provides new
information on intensive glycaemic control in terms of
both large-vessel and small-vessel end points.21,22
Intensive glycaemic control provided a significant
reduction in any diabetes end point (largely microvas-
cular) and MI. Use of metformin was also associated
with a reduction in diabetes end points, all-cause mor-
tality, and MI. However, neither intensive treatment
reduced the risk of PAD. Thus, intensive glycaemic
control alone is insufficient to prevent the peripheral
vascular complications of diabetes and underlines the
importance of the control of other risk factors (smok-
ing, hypertension, and hyperlipidaemia) in these
patients.
Recommendation 23: Control of diabetes in periph-
eral arterial disease
Patients with diabetes and peripheral arterial dis-
ease should have aggressive control and normalisa-
tion of blood sugar. Fasting blood sugars should
range from 80 to 120 mgldL, and postprandial sug-
ars should be <180 mgldL; haemoglobin Ale should
be <7.0%.
Diabetic patients are at particular risk of develop-
ing ulcers on their feet because of preexisting diabet-
ic sensory neuropathy. Foot deformity caused by a
motor neuropathy will also predispose to ulceration.
It is therefore important to educate diabetic patients
and their family about the importance of examining
the feet regularly, wearing protective footwear at
all times, avoiding abnormal pressure, and visiting
a specialised diabetic foot clinic if they have any
concerns.
Recommendation 24: Diabetic foot care in peripher-
al arterial disease
All diabetic patients with peripheral arterial dis-
ease should receive special advice and regular
supervision to minimise the risks of developing
diabetic foot complications.
Huperlipidaemia In PAD, the major lipid risk factors
for peripheral atherosclerosis are elevated LDL cho-
lesterol and triglyceride levels and low HDL choles-
terol levels.9,15,23,2u5 Lp(a) is a lipoprotein fraction
that is an independent risk factor for PAD.26
Unfortunately, there are no specific treatments for
elevated Lp(a) levels except to aggressively treat
abnormalities in other lipid fractions. Recent trials
support the observation that lipid modification is
associated with stabilisation or regression of femoral
atherosclerosis.27,28,29,3o,31 However, this was not
reproduced in the Probucol trial, in which treatment
did not change the severity of femoral atherosclero-
sis but prevented progression.v Neither was this
reproduced in the KAPS study, in which pravastatin
had no effect on the femoral artery but did reduce
plaques in the carotid.v Lipid modification in
patients with CAD is associated with a reduction in
the risk of vascular death. For example, simvastatin
reduced cardiovascular events signlflcantly,>' The
effect of lipid-lowering therapy on the clinical pro-
gression of PAD was evaluated in a subgroup analy-
sis of the Scandinavian simvastatin (4S) study." In
this study, simvastatin was associated with a 38%
risk reduction in the development or worsening of
claudication.
Current National Cholesterol Education Program
(NCEP) recommendations are to obtain a screening
lipid profile in all patients with PAD.36 For patients
with PAD who have elevated lipids, dietary restric-
tions should be the first advice." This may be effective
in treating hypertriglyceridaemia, which contributes
to progression of the disease.9 The treatment goals are
to achieve an LDL cholesterol less than 100 mg/dL (2.6
mmoI/L), which will usually require the use of drug
treatment. In addition, patients with a low HDL cho-
lesterollevel should be considered for niacin therapy.
Patients with low HDL and elevated triglyceride lev-
els in whom diet therapy fails should be placed on
fibrates. On the basis of reported trials, the use of
statins would result in avoiding one death per year in
640 patients treated." Additional studies in the PAD
population are needed to assess the effects of lipid
lowering on cardiovascular mortality and progression
of leg arterial disease (see also B 5.1.4, Cost-effective-
ness of Lipid Control in Intermittent Claudication, p
SI07).
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Recommendation 25: Lipid control in peripheral
arterial disease .
Because of the high incidence of coexistent coro-
nary disease and similar mortality risk to coronary
patients, patients with peripheral arterial disease
with a low-density lipoprotein (LOL) cholesterol
level greater than 125 mgldL should be placed on
therapy. In the first instance, a diet should be tried.
If this fails to achieve a goal of LOL cholesterol
level less than 100 mgldL, then medications should
be tried.
Huperieneion The effects of the treatment of hyper-
tension on the natural history of peripheral athero-
sclerosis have not been evaluated. In the claudicant,
the goal of hypertension therapy is to reduce the risk
of stroke, MI, and cardiovascular death, and this risk
factor should be controlled according to the JNC
guldelines.e- However, clinicians should be aware that
when drug therapy results in a large decrease in sys-
temic blood pressure, some patients may experience a
slight worsening of their claudication symptoms."
Nevertheless, it is important that such patients under-
stand the more important risk to their life from uncon-
trolled hypertension, albeit asymptomatic, than from
claudication. It also should be remembered that
hypertension can be secondary to renal artery disease,
and this is particularly likely in patients with PAD.
The plasma creatinine level should therefore be moni-
tored particularly carefully. The drug treatment of
hypertension can follow the same guidelines as in
patients without PAD. There is no good evidence that
beta blockers adversely affect mild to moderate clau-
dication.'?
Recommendation 26: Control of hypertension in
peripheral arterial disease
Peripheral arterial disease patients with hypertension
should have this risk factor controlled according to
Joint National Committee (VI) ONC [VI]) guidelines.
Hypercoaglliable states Hypercoagulable states
should be detected and treated where needed (see
Recommendation 14, p 557 and Table 13, p 555). The
only available treatment for these conditions is oral
anticoagulation.
Recommendation 27: Hypercoagulable states in
intermittent claudication
Patients with intermittent claudication who have a
hypercoagulable state and proven arterial or
venous thrombosis should be anticoagulated with
coumarins.
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Honiocfsicinc Recently, several reports have shown
a strong association between increases in plasma
homocysteine concentration and PAO.4\ This may be
an important risk factor in patients younger than 50
years who present with claudication. A meta-analysis
has clarified that at least the risk of CAD is increased
with a homocysteine level above 5 mmol/L." In
patients with CAD, elevated homocysteine levels are
also independent predictors of death." Therapy with
folic acid, vitamin 8 12, and vitamin B6 is effective in
lowering homocysteine levels, but the effects on vas-
cular disease severity have not been evaluated.
Critical Issue 7: Hyperhomocysteinemia in periph-
eral arterial disease
There is a need for therapeutic trials to define the
role of vitamin supplementation in preventing
peripheral arterial disease progression and cardio-
vascular death. Currently there is no solid evidence
to support the treatment of an elevated homocys-
teine level unless the symptomatic patient is
known to have folic acid or vitamin B12 deficiency.
Hormone replacetnent tlIerapy The potential benefits
of oestrogen plus progesterone therapy in preventing
cardiovascular events in women with a history of
CAD have been reported.r'
Antipuiielci tlIerapy
The Antiplatelet Trialists Collaboration reviewed 189
controlled studies involving secondary prevention of
cardiovascular events in over 100,000 patients with
cardiovascular symptoms. Overall, there was a 25%
decrease in fatal and nonfatal MI, stroke, and vascu-
lar death. Fewer than 4,000 patients with PAD were
entered (in 28 studies). They showed identical bene-
fit to the overall group, but, because of the low num-
bers, this was not statistically significant." The bene-
fit persisted for at least 3 years and was similar for
aspirin, at dosages ranging from 75 to 350 mg/d. In
the Physician's Health Study, low doses of aspirin
resulted in a 54% reduction in the risk of peripheral
arterial surgery as compared with placebo.w It
should be noted that higher doses of aspirin (greater
than 325 mg daily) are often associated with gas-
trointestinal intolerance."
Ticlopidine has been shown to reduce the risk of
stroke and fatal and nonfatal MI by 29% compared
with placebo.o The most recently studied antiplatelet
agent in PAD is clopidogrel, which, like ticlopidine,
blocks the activation of platelets by ADP. In 19,185
study subjects enrolled with cardiovascular disease,
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6,452 patients had PAD. All patients were ran-
domised to low-dose aspirin or clopidogrel and fol-
lowed up for an average of 1 to 3 years. In the PAD
subgroup, clopidogrel (as compared with aspirin)
resulted in a 23.8% relative risk reduction of
ischaemic stroke, MI, or vascular death, although the
95% confidence interval was wide (8.9%-36%), and
this included not only patients with IC but also those
following revascularisation.'? Additional studies will
be necessary to define the role of these new potent
(but more expensive) antiplatelet agents in the over-
all management of PADJO (see also B 5.1.3, The Cost-
effectiveness of Antiplatelet Therapy in Intermittent
Claudication, p 5106).
Recommendation 28: Antiplatelet therapy in
peripheral arterial disease
All patients with peripheral arterial disease (whether
symptomatic or asymptomatic) should be considered
for treatment with low-dose aspirin, or other approved
anti platelet (unless contraindicated), to reduce the risk
of cardiovascular morbidity and mortality.
Thepreceding discussion ofmeasures to modifyriskfactors,
includinganti-platelet therapy, directed at altering natural
historyand reducing systemicriskis presented illalgorithm
form ill B 4.1.3, page 573.
Exercise rehabilitation
In patients with claudication, convincing data indi-
cate that an exercise program can produce clinically
significant improvements in exercise performance
and community-based walking ability. However,
exercise can range from the physician recommending
unsupervised walking in the community to a formal
supervised exercise program on a treadmill. Several
studies suggest that some level of supervision is nec-
essary to achieve optimal results.51,52,53 In prospective
studies of supervised exercise conducted for 3
months or longer, there are clear increases
in treadmill exercise performance, and a lessening
of claudication pain severity during exer-
cise.54,55,56,57,58,59,60,6J,62,63,64,65,66
A recently published meta-analysis of these studies
showed an average 179% increase in initial claudica-
tion distance and a 122% increase in maximal walking
distance on the treadmill/" This meta-analysis includ-
ed uncontrolled observational studies as well. Table 15
summarises the results obtained in controlled trials.
The predictors of response to the training program
include a high level of claudication pain during the
training sessions and 6 months or longer of formal
training and walking exercise (vs other training
modalities). Treadmill exercise also has been shown to
be more effective than strength training or combina-
tions of training modalities.v Finally, there is virtually
no morbidity or mortality from exercise rehabilita-
tion.68 Several studies also have shown improvements
in peak exercise performance and peak oxygen con-
sumption with treadmill training. These changes are
important because, as a result, patients are able to per-
form activities of higher intensities such as climbing
stairs, gardening. and dancing, activities that were not
possible before training. These studies also have
shown that, at a given submaximal workload, exercise
training decreased heart rate, ventilation, and oxygen
consumptlon.s-v These changes may contribute to the
ability to sustain walking exercise for longer times
before claudication pain limits the activity.
In addition to evaluating changes in treadmill exer-
cise performance, some studies used patient-based
outcome assessment, SF-36 or WIQ, to determine
changes in functional status and quality of life with
exercise. This is important because the patient with
claudication is seeking treatment for a disabling
symptom that affects his or her daily activities." Using
this approach, supervised training has been shown to
improve the ability of the claudicant to walk longer
distances at faster speeds, with less severe claudica-
tion pain.54,71 These studies also showed improved
total caloric expenditure and physical functioning
using a variety of validated questionnaires. Thus, a
comprehensive approach needs to be used to assess
the benefits of any claudication therapy.
Exercise rehabilitation also has the potential to
favourably modify other cardiovascular risk factors.
Although not studied in a comprehensive fashion,
initial studies have shown an improvement in glu-
cose metabolism, a reduction in cholesterol and
triglyceride concentrations (when diet therapy was
also used), and enhanced smoking cessation.v-?
Improvements in these cardiovascular risk factors
are not typically seen with drug therapy for claudi-
cation or with bypass surgery or angioplasty. An
important issue is patient acceptability and compli-
ance with exercise training. Many patients may have
contraindications for exercise (eg, severe CAD, mus-
culoskeletal limitations, or neurological impair-
ments). Other patients may be unwilling to partici-
pate in supervised sessions if they have long dis-
tances to travel, if an appropriate rehabilitation pro-
gram is not available in their area, or if the expenses
incurred are too great. In a German study of 201
patients recommended for exercise, it was found that
34% had contraindications, and 36% of the remaining
patients refused to participate because of these same
arguments." However, an American study showed
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Table 15: Randornised, controlled trials evaluating the efficacy of exercise rehabilitation
Duration Change in Functional
Group n Intervention (mo) ACD(%) assessment
Larsen & Lassen.s 1966 T 7 Daily walks 6 183*+ No
C 7 Placebo tablet -6
Holm et al,n 1973 T 6 Exercise 4 133*+ No
C 6 Placebo tablet NC
Dahllof et .11,61 1974 T 11 Exercise 6 117*+ No
C 23 Placebo tablet NC
Dahllof et .11/,0 1976 T 8 Exercise 4 135*+ No
C 10 Placebo tablet 75*
Lundgren651989 T1 25 Surgery + exercise 6 263*+ No
T2 25 Surgery 173*+
T3 25 Exercise 151*+
Creasy et al,ss 1990 T1 13 Exercise 6 442*+ No
T2 20 Angioplasty 57
Hiatt et .11,54 1990 T 9 Supervised exercise 3 123*+ Improved
C 10 Control 20* NC
Mannarino et al,66 1991 T1 10 Exercise + antiplatelet 6 105*+ No
T2 10 Exercise 86*+
T3 10 Antiplatelet 38*
Hiatt et .11,55 1994 T1 9 Supcrvised exercise 3 74*+ Improved
T2 8 Strength training 36* NC
C 10 Control -1 NC
Regensteiner et alP 1997 T1 10 Supervised exercise 3 137*+ Improved
T2 10 Home exercise 5 NC
Patterson et al,69 1997 T1 19 Supervised exercise 6 195*+ Improved
T2 19 Home exercise 83* Improved
Abbreviations: T, treated group; C, control group; Functional assessment, use of questionnaire to evaluate community-based func-
tional status; NC, no change.
*p < 0.05 compared with baseline.
+p < 0.05 difference between groups. For the Creasy study, the data given are for the 12-month follow-up point.
that only 9% of patients referred for supervised exer-
cise training were excluded on screening for the pro-
gram.68 These exclusions were all for severe cardiac
ischaemia on the initial treadmill test. In patients
enrolled, 73% were able to complete the program
without difficulty. Thus, when offered, most patients
are able to enroll and successfully complete a train-
ing program for their claudication.
An important aspect of exercise is that patients
need more than the simple recommendation by the
physician to engage in walking exercise at home. In
one study, patients with Ie were randomised to a 3-
month program of supervised exercise or home-
based exercise. Patients exercising at home were
given detailed instructions by a rehabilitation nurse
at the start of the program. They were also contact-
ed weekly by phone to assess compliance and pro-
vide encouragement. Whereas the supervised
patients had the expected improvements in tread-
mill exercise performance and quality of life, those
patients trained at home realised no benefit.P Thus,
exercise is effective primarily when performed in a
supervised environment. However, unsupervised
training may be more effective than no training
at all.
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Tire exercise prescription
Exercise sessions are typically held 3 times a week for
approximately 1 hour each, and 3- to 6-month periods
of training are customary. During the exercise ses-
sions, rest periods (induced by claudication) are inter-
spersed with bouts of treadmill walking. The patient
walks on the treadmill until a mild or moderate level
of pain is reached (scored as "3" or "4" on a 1-5 scale
as previously described). At that point, the patient
rests until the pain abates. The initial training work-
load is determined from the symptom-limited maxi-
mal treadmill test on entry, such that the intensity of
the treadmill exercise is set to the workload that ini-
tially brings on claudication pain in the patient. In
subsequent visits, the speed or grade is increased if the
patient is able to walk for 10 minutes or longer at the
lower workload without reaching moderate claudica-
tion pain. Either speed or grade can be increased, but
an increased grade is recommended if the patient can
already walk at 2 mph (3.2 km/h). An additional goal
of the program is to increase patient walking speed up
to the normal 3.0 mph (4.8 km/h) from the average
PAD patient walking speed of 1.5 to 2.0 mph (approx-
imately 2.4-3.2 km/h).
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The precise mechanism behind improvement of walk-
ing ability with exercise is not established. Collateral
development seems unlikely because ankle pressures
and limb flow do not show any impressive increases
after exercisel5,76 Even though some improvement in
haemodynarnic parameters are shown, they are poorly
correlated to an increased walking capacity» Other pos-
sible explanations might be an improved metabolic
capacity in the muscles and altered gait using more prox-
imal non-ischaernic muscle, by analogy to amputees
walking with a prosthesis. 61•77,7s A further question is
whether pain-developing exercise has any negative
impact. It has been shown that patients with IC have an
increased rnicroalbuminuria after exercise, supporting
the interpretation that an ischaemia reperfusion injury
takes place." This is also supported by the findings of
thromboxane and neutrophil changes in claudicants dur-
ing and after walking.v By contrast, a recent study
showed that treadmill exercise is not associated with a
change in any plasma marker of endothelial damage,»
Sununaru: Exercise training
Numerous trials provide evidence that the walking
capacity and overall functional status are increased by
exercise training in patients with disabling claudica-
tion. The most effective programs are supervised,
employ walking exercise, and last 3 to 6 months.
Maintenance of regular exercise, whether supervised
or not, needs to be continued indefinitely or the bene-
fit wiII eventually be lost.
Recommendation 29: Exercise training in intermit-
tent claudication
A program of exercise therapy (preferably super-
vised) should always be considered as part of the
initial treatment for patients with intermittent clau-
dication.
B 4.1.3
Treatment to Alter Natural History and Reduce Systemic Risk
II AnJ(JC:Of8Cmal pressure mcex 11
Confirm PAD with intermittent claudication
IIAssess cardiovascular + Assess disabilit;" Irisk factors symptom seventy
I I
Initial evaluation: Evaluate and treat
• Haemoglobin intermittent
• Serum creatinine Claudication as
• Smoking history per other
• Lipid profile Algorithms
• Hypertension
• Diabetes See B 4.6.1
and B 4.6.2
Special investigations:
• Hypercoagulability screen
• Homocysteine level
• Lp(a)
• Other
I.Modify risk factors I
• Antiplatelettherapy
I
I II?iabctes treatmentIIH~'l'Cfhomocysteinemia II HypereoagulableandIIlf>~on treatment I
• HbAlC < 7.0% ? elate or Bu artenal thrombosis • 0 low mc VI guidelines
•Anticoagulate
Smoking cessation Lj~dgoals
'Behavior modification
'L L cholesterol < 100 mgldL
'Nicotine replacement
'Reduce trityceride
-Bupropion
'Raise HD cholesterol
SF-36 =Medical Outcomes Short Form 36 Questionnaire
V.1Q =Walking Impairment Questionnaire
PVR =pulse volume recording
VWF =velocity waveform analysis
MRA = magnetic resonance angiography
mc =Joint NationalCommission
HbAIC = hcmoglobinAIC
LDL =low-denslt)' lipoprotein
HDL =high-denSlt)' Itpoprotcin
•Disability as defined by the individual patient
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B 4.2
Pharmacotherapy for Symptoms of Intermittent
Claudication
B 4.2.1
Introduction
Patients with intermittent claudication mostly receive
drug treatment for coexisting disease (eg, hyperten-
sion), risk factor modification (eg, hyperlipidaemia),
and as prophylaxis against thrombotic events associ-
ated with atherosclerosis (eg, antiplatelet drugs). No
pharmacological agent has proved efficacious enough
in providing significant reduction or elimination of
symptoms of claudication to gain Widespread accept-
ance and use for improving walking. However, a
number of types of drugs have been promoted for this
indication, with varying evidential support, and these
will be considered in this section. These drugs are fre-
quently grouped together under the heading "vasoac-
tive agents," partly because of their multiplicity of
potential mechanisms of action. Some of the drugs
have been distinguished as "rheologic agents," but
for others such as prostanoids, the mode of action is
still not well delineated. These drugs should not
replace exercise programs and other lifestyle adjust-
ments described in B 4.1.2, Basic Treatment (p 568).
However, they have a place as adjunctive treatment
where invasive therapy is not indicated, in those who
cannot or will not follow exercise therapy or in those
who have not sufficiently benefited from it (see D
4.13.5, Adjuvant Therapy, p 5211). Table 16 and Figure
20 show results of randomised, placebo-controlled,
double-blind trials of pharmacotherapy in Ie.
B 4.2.2
Established Drugs With Proven but Small Benefit in
Improving Claudication
Pell toxiJtJllille
Pentoxifylline improves red cell deformability, lowers
fibrinogen levels, decreases platelet aggregation, and
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has been shown to increase walking distance in
patients with PAD. In early controlled trials, the drug
produced a 22% improvement over placebo in ICD
and a 12% improvement in the ACD.I However, these
percent improvements were expressed as the mean
difference between week 2 and week 24. The actual
improvement over placebo from entry to 6 months in
ACD was 18%, but this difference was not statistically
significant. A more recent study confirmed these
results, with a 21% improvement over placebo (p =
0.09).2The study showed that a subgroup of patients
with symptoms for longer than a year and an ABPI <
0.80 responded better to the drug. Importantly,
patient-based questionnaires to assess efficacy have
not been employed in the clinical trials of pentoxi-
fylline, so the actual clinical benefit of the drug has not
been fully defined.
Naflidrofllryl
Naftidrofuryl has been available for treating IC for over
20 years. It is a 5HT antagonist and may improve aero-
bic metabolism in oxygen-depleted tissues and possibly
reduce erythrocyte and platelet aggregation.' In four
placebo-controlled studies, Naftidrofuryl was more
effective than placebo in improving walking dis-
tance,4.5.6.7 and a further study showed no significant
difference,"
Bltjlomedil
Buflomedil has an alpha-1 and -2 adrenolytic effect. It
has been shown to decrease vasoconstriction. It has
also been shown to have some effect on platelets, red
cell deformability, and a weak calcium antagonist
effect. Buflomedil has been available for the treatment
of IC in some countries for over 10 years. Two rela-
tively small studies, conducted more than 10 years
ago, showed a significantly greater improvement in
absolute walking distance with Buflomedil compared
with placebo.vw
Cilostazol
Cilostazol is a phosphodiesterase III inhibitor with
vasodilator and antiplatelet activity," The first pub-
lished double-blind trial showed a 47% increase in
ACD in the treatment group compared to 13%
increase in the placebo group (Table 16).12 This trial
also showed that all subgroups of patients (age, smok-
ing status, gender, race, and diabetes) responded
